A one-time dose of DURVEQTIX has reduced bleeds post-treatment compared to standard of care with a median annualized bleed rate (ABR) of zero bleeds (range 0 to 9.9)
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
SUPERNOVA is a large Phase III global trial providing the only efficacy data in immunocompromised patients
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
Sales reflect continued strong growth in oncology and vaccines
The company has received five final approvals
The product is expected to be launched in December 2023
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
Subscribe To Our Newsletter & Stay Updated
